sodium zirconium cyclosilicate 10000 MG Powder for Oral Suspension [Lokelma]
- RxCUI
- 2053927
- RxNorm name
- sodium zirconium cyclosilicate 10000 MG Powder for Oral Suspension [Lokelma]
- Display name
- sodium zirconium cyclosilicate 10000 MG Powder for Oral Suspension [Lokelma]
- Full name
- sodium zirconium cyclosilicate 10000 MG Powder for Oral Suspension [Lokelma]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:08
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LOKELMA | SODIUM ZIRCONIUM CYCLOSILICATE | A-S Medication Solutions | 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8 | 2026-03-26 | Warnings, Adverse reactions | 2053927 |
| LOKELMA | SODIUM ZIRCONIUM CYCLOSILICATE | AstraZeneca Pharmaceuticals LP | 90bf8e28-748d-4e4b-a19f-9cf483370eff | 2024-02-08 | Warnings, Adverse reactions | 2053927 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 90bf8e28-748d-4e4b-a19f-9cf483370eff | sodium zirconium cyclosilicate 10000 MG Powder for Oral Suspension [Lokelma] | SBD | 28 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20240208 |
| 90bf8e28-748d-4e4b-a19f-9cf483370eff | Lokelma 10 GM Powder for Oral Suspension | SY | 28 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20240208 |
| 90bf8e28-748d-4e4b-a19f-9cf483370eff | Lokelma 10 GM Powder for Oral Suspension | PSN | 28 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20240208 |
| 90bf8e28-748d-4e4b-a19f-9cf483370eff | Lokelma 10000 MG Powder for Oral Suspension | SY | 28 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20240208 |
| 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8 | sodium zirconium cyclosilicate 10000 MG Powder for Oral Suspension [Lokelma] | SBD | 8 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20260326 |
| 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8 | Lokelma 10000 MG Powder for Oral Suspension | SY | 8 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20260326 |
| 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8 | Lokelma 10 GM Powder for Oral Suspension | SY | 8 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20260326 |
| 8833d6e6-33ab-4ea9-b78f-3ec30a904ef8 | Lokelma 10 GM Powder for Oral Suspension | PSN | 8 | These highlights do not include all the information needed to use LOKELMA ® safely and effectively. See full prescribing information for LOKELMA ® . LOKELMA ® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018 | 20260326 |